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Abstract 
Cough is the most common symptom of respiratory diseases. The results of management of chronic cough in adults are still un-
satisfactory. Unexplained and difficult-to-treat chronic cough causes significant impairment in patients‘ quality of life. The results 
of recent studies suggest that speech therapy (speech language intervention) is one of the few methods which are usefull in 
management of persistent chronic cough. We present a case of a patient with chronic cough due to chronic nonallergic rhinitis 
and gastroesophageal reflux disease, who had been unsuccessfully treated for 18 years. In the patient speech therapy resulted 
in a significant decrease of cough severity and improvement of quality of life. 
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Introduction
Cough is one of the most common symptoms 
of respiratory diseases. Chronic cough (CC) (las-
ting > 8 weeks) affects about 10–20% of adults [1]. 
Due to a large number of CC causes, the causal 
diagnosis is often challenging. Thorough analysis 
of medical history that includes symptoms, co-
morbidities and medications should be a starting 
point for differential diagnosis of CC causes. 
Chest radiograph (CXR) is a pivotal diagnostic 
procedure in the further diagnostic work-up. This 
may reveal not only pulmonary but also extrapul-
monary abnormalities that are associated with CC. 
On the other hand, in a significant proportion of 
patients with CC, CXR does not show any abnor-
mal findings. The most common causes of CC in 
non-smoking adults with normal CXR result, are 
as follows: upper airway cough syndrome (UACS), 
gastroesophageal reflux disease (GERD), asth-
ma, nonasthmatic eosinophilic bronchitis and 
treatment with angiotensin convertase enzyme 
inhibitors (ACEI) [1, 2]. 
The results of management of CC in adults 
are highly unsatisfactory [1, 3, 4]. It may be a re-
sult of either ineffective management of properly 
diagnosed underlying diseases (difficult-to-treat 
CC) or failure to diagnose the cause of CC. Ac-
cording to ACCP recommendations, unexplained 
chronic cough (UCC) is diagnosed in as many as 
5–10% of all adults with CC [4]. Persistent CC 
significantly impairs the quality of life [5]. 
There are only few methods of management 
of patients with UCC [4]. These include pharma-
cological treatment with gabapentin and speech 
and language intervention (the other names: 
speech or voice therapy). The latter is the most 
documented method of management of UCC or di-
fficult-to-treat cough [4]. Speech therapy consists 
of education, learning strategies to reduce cough, 
respiratory and speech exercises [6–8]. We pre-
sent a case of a patient with persistent, difficult- 
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-to-treat chronic cough due to gastroesophageal 
reflux disease, who was finally succesfully treated 
with speech therapy.
Case report
44-year-old, non-smoking female, a nurse, 
was referred to the Department of Internal Medi-
cine, Pulmonary Diseases and Allergy to diagnose 
the cause of CC, which had persisted for appro-
ximately ten years. Previously, the patient had 
been unsuccessfully treated with many different 
pharmacotherapies, including antileukotrienes, 
inhaled corticosteroids, bronchodilators and 
antibiotics. 
The patient was admitted to our department 
first in 2008 because of persistent CC. The begin-
ning of cough had been associated with an acute 
respiratory infection. The cough was dry, occured 
mainly in the morning and in the evening. It was 
accompanied by runny nose and nasal congestion. 
The patient denied chest pain, shortness of bre-
ath, haemoptysis or general symptoms like fever 
or weight loss. The physical examination revealed 
no significant abnormalities. CXR showed small, 
fibrotic plate atelectasis in the middle field of 
the right lung, but computed tomography (CT) 
of the chest revealed that the lung parenchyma 
and mediastinal organs were normal. The result 
of spirometry was within the norm and metha-
choline inhalation challenge was negative (PC20 
> 16 mg/ml), which allowed to exclude asthma 
and other obstructive airway diseases. There were 
no eosinophils in induced sputum, which con-
tradicted the diagnosis of nonasthmatic eosino-
philic bronchitis. Skin prick tests with common 
aeroallergens were negative. CT scan of the para-
nasal sinuses showed small beads of the mucous 
membrane in the maxillary sinus, deviated nasal 
septum and enlarged right middle turbinate. The 
patient was consulted by the laryngologist, who 
diagnosed chronic nonallergic rhinosinusitis and 
recommended intranasal glicocorticosteroids. Vi-
deolaryngoscopy revealed redness of the posterior 
part of the larynx suggesting possibility of laryn-
go-pharyngeal reflux. The function of the larynx 
was normal. In order to exclude gastroesophageal 
reflux disease as a potential cause of cough, 24-
hour esophageal pH monitoring was performed, 
which revealed acid reflux episodes (DeMess-
ter score 21.5, normal range < 14.7), but no 
relation ship between cough and reflux episodes 
was documented. The treatment with intranasal 
budesonide, anti-reflux diet and pantoprazol 40 
mg bid was introduced for 8 weeks, but it failed 
to reduce cough intensity. Therefore, esophageal 
24-hour multichannel intraluminal impedance-
pH monitoring was performed that confirmed 
the presence of weakly acid reflux reaching the 
proximal esophagus and larynx. Neither diet, life 
style modification nor medications (pantoprazol, 
esomeprazol, ranitidine, cisaprid) resulted in 
reduction of cough intensity. Difficult-to-treat 
cough due to UACS (chronic nonallergic rhinosi-
nusities) and GERD (weakly acid) was diagnosed. 
The patient had been treated because of cough in 
our outpatient clinic from 2008 till 2015.
In 2015, a trial of treatment with gabapentin 
(300 mg bid) was introduced, but was ineffective 
and had to be ceased due to adverse effects (di-
zziness and nausea). As all treatment attempts 
were unsuccessful and CC significantly affected 
patients‘ quality of life, the patient was referred 
to speech therapy. Before initiation of speech 
therapy, cough severity and its influence on 
quality of life was assessed in accordance with 
ERS guidelines [9]. We applied Visual Analogue 
Scale (VAS) for subjective assessment of cough 
severity and Leicester Cough Questionnaire (LCQ) 
for evaluation of influence of cough on patients‘ 
quality of life [9,10]. Moreover, cough challenge 
test with capsaicin was performed to assess the 
sensitivity to inhaled irritants [9,10]. 
Speech therapy was conducted by a speech 
therapist using a method developed by our team 
based on the technique described by Vertigan et 
al. [6]. It included education of vocal hygiene, 
teaching strategies to relax diaphragm and redu-
ce cough and laryngeal irritation. Breathing and 
vocal exercises along with education were used. 
The entire therapy consisted of eight 45-minute 
sessions once a week, 2 of which were individual 
and 6 were continued in a group. 
After the speech therapy, the patient declared 
significant, subjective improvement, that was 
confirmed by reduction of cough severity measu-
red by VAS and improvement in quality of life 
documented in LCQ. There was no change in the 
threshold of cough provocation in the capsaicin 
test. The detailed results of VAS, LCQ and cap-
saicin provocation test before and after therapy 
are shown in Table 1. In the patient opinion, the 
breathing exercises were the most effective com-
ponent of the speech therapy.
Discussion
Although various therapeutic approaches to 
patients with CC have been evaluated, there is 
no convincing data on the effectiveness of these 
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Table 1. Results of the speech therapy
Before speech tehrapy After speech therapy
Severity of cough measured by VAS (mm) 75 28
Quality of life measured by total LCQ
   physical domain of LCQ
   psychological domain of LCQ









Sensitivity of cough reflex measured  
by capsaicin challenge (µM)
C2–7.84 C2–7.84
VAS — visual analogue scale, range 0–100 mm; LCQ — Leicester Cough Questionnaier (LCQ), range 3–21 points; the higher the value, the better quality of life in 
patients with cough; C2 — concentration of capsaicin, which induce 2 coughs during provocation challenge test with capsaicin
therapies, and the management of chronic cough 
is still challenging [4]. Our patient had been 
unsuccesfully treated for 18 years (1998–2016) 
before her cough was significantly reduced due 
to the speech therapy. Although in most patients 
CC is a symptom of non-life-threatening disease, 
it significantly lowers quality of life, in both 
physical and psychosocial domain [1, 5]. In many 
aspects the decrease of life quality in patients 
with CC is comparable to that experienced by 
patients with the chronic obstructive lung dise-
ase [1]. Therefore, the effective therapies for CC 
are one of the most important unmet needs in 
respiratory diseases. 
The effectiveness of CC management, however, 
is highly unsatisfactory [3, 11, 12]. In the study by 
Haque et al. [3] 42% of patients with CC did not 
improve despite causal treatment. Our previous 
study showed that only 55% of patients with CC 
reported significant decrease in cough severity as a 
result of applied therapy [11]. Similarly, in the re-
cently published survey study approximately 36% 
of patients with CC declared no effect of cough 
therapy [12]. According to the ACCP guidelines, 
persistent untreatable cough refers to 5–10% of all 
CC patients undergoing treatment and up to 46% of 
patients managed in specialised cough clinics [4]. 
Among them, there are patients with recognised 
cough reasons, but refractory to cough therapy 
and patients with unexplained cough causes [4]. 
Since UACS and GERD had been diagnosed 
as the causes of CC in our patient, the caus-
ative treatment directed to these two conditions 
seemed to be the most reasonable therapeutic 
option. However, the effectiveness of treatment of 
CC due to GERD is doubtful. One meta-analysis 
of treatment efficacy with proton pump inhibitors 
(PPI) failed to confirm their effectiveness [13]. 
Similarly, the treatment of cough due to UACS, 
especially nonallergic rhinosinusitis, is thought to 
be wearisome and only partially successful [14]. 
The above comments may explain the failure of 
pharmacotherapy in our patient. 
The unsatisfactory effectiveness of CC man-
agement contributed to the popularity of the 
theory of cough hypersensitivity syndrome [15]. 
Its pathophysiology is still not absolutely clear, 
it probably results from central and peripheral 
sensitisation, usually after a viral infection. Thus, 
regardless of CC reason, the failure of cough 
treatment may result from hypersensitivity of 
cough reflex [16]. 
In fact, there are only two methods available 
for management of patients with refractory CC: 
centrally acting neuromodulators (gabapentin and 
pregbalin) or speech and language therapy [4]. As 
the usage of gabapentin is limited due to its side 
effects, the speech therapy is the most promising 
method of management of UCC. This technique 
is adapted from the treatment of hyperfunctio-
nal voice disorders. The first studies concerning 
speech therapy techniques in treatment of CC 
came from the 80s of 20th century, while the 
first randomised trial was published in 2006 [6]. 
Speech therapy for CC is multifactorial inter-
vention, which may include different elements: 
education about cough, identification of cough 
triggers, instruction on cough suppression tech-
niques, breathing exercises, vocal hygiene and hy-
dration techniques and sometimes some forms of 
counselling. These treatment techniques general-
ly are delivered by speech and language therapists 
or physiotherapists and usually consist of 2–4 
sessions [7, 8, 17]. The mechanism of reducing 
cough by speech pathology intervention is yet to 
be determined. Perhaps, breathing exercises allow 
to relax the throat, neck, and shoulder muscles, 
which may help to reduce the adductor activity of 
the vocal folds during expiration in patients with 
CC and paradoxical vocal fold movement [7]. To 
our knowledge, the speech therapy has not been 
available for patients with CC in Poland. Hence, 
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we undertook the task of working out the voice 
therapy for patients with CC treated in our insti-
tution. The speech therapy was implemented and 
performed by the phoniatrist (DR) and speech and 
language therapists (AŁ). It consisted of education 
about cough and vocal hygiene, identification of 
cough triggers, instruction on cough suppres-
sion techniques, conscious breathing, relaxing 
and speech exercises. They included breathing 
control, diaphragmatic breathing and relaxed 
breathing control techniques. Continuation of the 
therapy in a group was a new approach, worked 
out by our team as a component of psychological 
support for the patients.
An important problem in all studies on ma-
nagement of CC is how to define the response to 
cough therapy. Numerous studies were performed 
to define clinical tools for measurement of cough. 
Among them, there are cough monitors, cough 
specific quality of life questionnaires, VAS and 
sensitivity to inhaled cough irritants measured in 
cough challenge test [9, 10]. To follow the effect 
of speech therapy in our patient, we used the abo-
ve mentioned tools with the exception of cough 
monitor. Both VAS as a subjective scale of cough 
severity, and Polish version of LCQ [18] showed 
significant improvement. These findings are 
similar to results published by other authors [6, 
19]. Interestingly, there was no change in cough 
responsiveness assessed by capsaicin challenge, 
and this is also consistent with results of other 
authors [19]. 
Although speech therapy is a useful method of 
CC treatment, the persistent CC still remains a ma-
jor problem. Therefore, the studies concerning new 
antitussive drugs are necessary. Recently the phase 
2 clinical study has been published by Abdulqawi 
et al. [20], who presented P2X3 receptor antagonist 
(AF-219) as an effective drug in refractory chronic 
cough. Further studies are in progress.
In conclusion, the speech therapy was the 
most effective method of treatment of persistent 
CC in our patient. As CC is a common complaint 
and the effectiveness of pharmacological thera-
pies are rather limited, the speech therapy may 
become useful therapeutic approach for numero-
us patients with persistent CC.
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